Atlas Trials

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Clinical trial NCT04839341 · COMPLETED

Trial details

NCT number
NCT04839341
Sponsor
Apollomics Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory AML
Start date
2021-02-24
Primary completion
2024-06-28
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.